

NETARSUDIL-LATANOPROST eye drops (Roclanda® ▼) for open-angle glaucoma or ocular hypertension

The Cheshire and Merseyside Area Prescribing Group does not currently recommend the prescribing of NETARSUDIL-LATANOPROST eye drops (Roclanda® ▼) for open-angle glaucoma or ocular hypertension.

GREY

Netarsudil-latanoprost is indicated for the reduction of elevated intraocular pressure (IOP) in adult patients with primary open-angle glaucoma or ocular hypertension for whom monotherapy with a prostaglandin or netarsudil provides insufficient IOP reduction.^[1]

This recommendation will be reviewed when the <u>NICE TA</u> is published.

In the meantime, clinicians should continue to follow national guidance, local pathways, and local formulary choices for the treatment of open-angle glaucoma or ocular hypertension:

- > NICE guideline [NG81]: Glaucoma: diagnosis and management, updated 26 January 2022
- > Cheshire APG Formulary Chapter 11: Eye
- > Pan Mersey APC Formulary Chapter 11: Eye

References

1. Santen UK Limited. Summary of Product Characteristics; <u>Roclanda 50 micrograms/ml + 200 micrograms/ml eye drops, solution</u>, 8 December 2022. Accessed 20 July 2023.

Note: Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.

Date of issue: 04 Aug 2023 Prescribing policy statement

Review date: Aug 2025 (or earlier if there is significant new evidence relating to this recommendation)

Area Prescribing Group administration provided by Midlands and Lancashire Commissioning Support Unit

Version: 1.0